Alere announced the launch of its Alere iCup Rx Drug Screen, a test designed to detect five of the most commonly misused and abused drugs—benzodiazepines, buprenorphine, methadone, opiates, and oxycodone—in urine.
Alere iCup Rx is a lateral flow chromatographic immunoassay that allows addiction specialists and physicians to screen for abuse and help improve patient compliance. The iCup Rx is the first rapid urine test to validate five of the most relevant prescription drugs at once.
“An easy-to-use test that provides actionable results during a patient visit is a valuable first-line tool to detect potential opioid abuse and, when it occurs, to get these patients the specific addiction treatment they need,” said Robert L. DuPont, MD, Clinical Professor of Psychiatry at the Georgetown University School of Medicine and Director of the National Institute on Drug Abuse (NIDA).
The rapid detection tests consists of a self-contained collection cup and test device with auto-activated results seen in 5 minutes with no tipping of the cup. It also features a specimen validity test (SVT) to track any specimen tampering and adulteration. The iCup Rx has a lower opiate cutoff level compared to most other urine drug assays at 300ng/mL.
Results from drug assays are only preliminary and must be confirmed with more specific methods (eg, gas chromatography-mass spectrometry, liquid chromatography-tandem mass spectrometry).
For more information call (877) 441-7440 or visit Alere.com.